ILK and familial dilated cardiomyopathy: In other DCM models, a limited number of disease modifying therapeutic approaches were attempted, including the overexpression of Serca2a by viral-vector gene-therapy (Sun et al., 2012), and the modulation of SERCA/PLN through the mechanoreceptor protein integrin-linked kinase (ILK) (Traister et al., 2014).